Brexit, Pharmaceuticals and SPCs

Author: James A. Stones
IP News

Supplementary Protection Certificates (SPCs) can extend the 20 year term of patents relating to medicinal products by up to 5 years (or 5½ years in the case of paediatric medicines).  This is intended to compensate the developers of such products for the time taken to obtain authorisation to place them on the market.

However, due to the nature of the existing legal and regulatory framework, after the UK leaves the European Union, SPC protection may no longer be  available to UK-based companies developing these products unless they “set up shop” as it were in the EU or EEA.  The issues are discussed in detail in an article in the British Journal of Pharmacy, written by Jamie Fraser and James Stones of Beck Greener, which can be found here:

close popup

IP updates signup

Subscribe to our IP news updates mailing list

If you would like to receive our IP updates, please complete the form below. By signing up, you are agreeing to receive IP updates from us, but you can unsubscribe at any time.

* indicates required
Select your IP interests

Please select all the ways you would like to hear from Beck Greener:

We take your privacy seriously and you can manage your preferences or unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website at

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.